Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients

摘要: Neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) have their biological half-lives controlled by dipeptidyl peptidase IV (DPP IV/CD26). Several lines of evidence suggest the involvement NPY in regulation rheumatoid arthritis (RA), VIP has already been identified as a potent anti-inflammatory factor that reduces joint inflammation. The role DPP IV/CD26 pathogenesis RA indicated, but its mediator actions involving not well investigated, so aim this study was to find an association between NPY, VIP, patients. Assessment some other inflammatory markers carried out 20 patients being treated with different types drugs. Control group consisted 18 osteoarthritis Synovial fluid serum content investigated molecules determined ELISA activity measured spectrophotometrically. Immunodetection showed elevated levels patients, significant increase synovial fluid, while concentration were significantly decreased both serum. Positive correlations (R = 0.6961), 0.7029) found. In group, concentrations affected administration results indicate connection concentration, suggesting potential these immunomodulation RA.